RBM15 and autosomal dominant cerebellar ataxia: The IP assay showed that SCA treatment—both alone and combined with 5‐FU—significantly reduced ACLY‐RBM15 binding, with the combination exhibiting more pronounced effects (Figure S7d,e, Supporting Information).